[
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=d0ad55b000473e66d3d4edccf2b3641af1e487eb26107fe56d81b97c3ecd5a0d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744129920,
      "headline": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
      "id": 133824721,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=d0ad55b000473e66d3d4edccf2b3641af1e487eb26107fe56d81b97c3ecd5a0d"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis",
    "summary": "European Commission approves ABBV's Rinvoq for its eighth indication, giant cell arteritis.",
    "url": "https://finnhub.io/api/news?id=3770741deb59d49197223c629edb50225ba3a0352071fea69192947755159d36",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744118100,
      "headline": "AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis",
      "id": 133823361,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "European Commission approves ABBV's Rinvoq for its eighth indication, giant cell arteritis.",
      "url": "https://finnhub.io/api/news?id=3770741deb59d49197223c629edb50225ba3a0352071fea69192947755159d36"
    }
  },
  {
    "ts": null,
    "headline": "Goldman turns cautious on major pharma names, sees select upside at Eli Lilly",
    "summary": "Investing.com -- Goldman Sachs initiated coverage on several large-cap pharmaceutical companies, taking a cautious stance on Bristol-Myers Squibb (NYSE:BMY), Pfizer (NYSE:PFE), and AbbVie (NYSE:ABBV), while upgrading Eli Lilly (NYSE:LLY) to a Buy on strong growth prospects in obesity treatments.",
    "url": "https://finnhub.io/api/news?id=79226bcb7596285f28ccfc803c594c16b98e3dc7715b9d1f3c7d0d9b11ba1be3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744117697,
      "headline": "Goldman turns cautious on major pharma names, sees select upside at Eli Lilly",
      "id": 133820740,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Investing.com -- Goldman Sachs initiated coverage on several large-cap pharmaceutical companies, taking a cautious stance on Bristol-Myers Squibb (NYSE:BMY), Pfizer (NYSE:PFE), and AbbVie (NYSE:ABBV), while upgrading Eli Lilly (NYSE:LLY) to a Buy on strong growth prospects in obesity treatments.",
      "url": "https://finnhub.io/api/news?id=79226bcb7596285f28ccfc803c594c16b98e3dc7715b9d1f3c7d0d9b11ba1be3"
    }
  },
  {
    "ts": null,
    "headline": "Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?",
    "summary": "Style Box ETF report for SCHD",
    "url": "https://finnhub.io/api/news?id=8bf3f5944bba48d3c6db5b4235bc8357499eb7b8e486ef0dc4e86075b067c9e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744107608,
      "headline": "Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?",
      "id": 133823365,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Style Box ETF report for SCHD",
      "url": "https://finnhub.io/api/news?id=8bf3f5944bba48d3c6db5b4235bc8357499eb7b8e486ef0dc4e86075b067c9e4"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Gets Expanded Europe OK for Rinvoq in Giant Cell Arteritis",
    "summary": "AbbVie Gets Expanded Europe OK for Rinvoq in Giant Cell Arteritis",
    "url": "https://finnhub.io/api/news?id=74cefe3aad51be371aa2e382d213e4e8695b852ab7d958530f7172efea4abc13",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744092480,
      "headline": "AbbVie Gets Expanded Europe OK for Rinvoq in Giant Cell Arteritis",
      "id": 133772430,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Gets Expanded Europe OK for Rinvoq in Giant Cell Arteritis",
      "url": "https://finnhub.io/api/news?id=74cefe3aad51be371aa2e382d213e4e8695b852ab7d958530f7172efea4abc13"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Announces European Commission Approval of RINVOQ速 (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis",
    "summary": "AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ速 (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in adult patients. RINVOQ is the first and only oral JAK inhibitor approved in the EU, as well as Iceland, Liechtenstein and Norway, for the treatment of adult patients with GCA.",
    "url": "https://finnhub.io/api/news?id=9c88839c4b6bedf435fa253c4af156d5898e18ce42ee473ccf46b776df797f5f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744092000,
      "headline": "AbbVie Announces European Commission Approval of RINVOQ速 (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis",
      "id": 133823366,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ速 (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in adult patients. RINVOQ is the first and only oral JAK inhibitor approved in the EU, as well as Iceland, Liechtenstein and Norway, for the treatment of adult patients with GCA.",
      "url": "https://finnhub.io/api/news?id=9c88839c4b6bedf435fa253c4af156d5898e18ce42ee473ccf46b776df797f5f"
    }
  }
]